Tumor multidrug resistance (MDR) is a serious clinical challenge that significantly limits the effectiveness of cytotoxic chemotherapy. As such, complementary therapeutic strategies are being explored to prevent relapse. The altered metabolic state of cancer cells, which perform aerobic glycolysis, represents an interesting target that can enable discrimination between healthy cells and cancer ...

In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170to 180kDa glycoprotein known as P-glycoprotein (Pgp) or human MDR1 protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, includi...

In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170to 180kDa glycoprotein known as P-glycoprotein (Pgp) or human MDR1 protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, includi...

the emergence of multidrug resistance (mdr) and extensively drug resistance (xdr) in acinetobacter baumannii has made an important challenge in the treatment of infections caused by this organism. the ability of carbapenemase production is one of the main mechanisms for the emergence of mdr and/or xdr in a. baumannii. the aim of this study was to detect carbapenemase producer a. baumannii. in t...

In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170to 180kDa glycoprotein known as P-glycoprotein (Pgp) or human MDR1 protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, includi...

In acute myeloid leukemias (AMLs), multidrug resistance (MDR) is frequently, but not always, caused by the MDR1 gene product, a 170to 180kDa glycoprotein known as P-glycoprotein (Pgp) or human MDR1 protein (1). It is characterized by broad resistance to several structurally, chemically, and pharmacologically distinct chemotherapeutic compounds. Many theories explain how Pgp affects MDR, includi...

Multidrug resistance (MDR) attenuates the chemotherapy efficacy and increases the probability of cancer recurrence. The accelerated drug efflux mediated by ATP-binding cassette (ABC) transporters is one of the major MDR mechanisms. This study investigated if TTT-28, a newly synthesized thiazole-valine peptidomimetic, could reverse ABCB1-mediated MDR in vitro and in vivo. TTT-28 reversed the ABC...

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteri...

Background: Acinetobacter baumannii is a highly virulent bacterium. It causes opportunistic and nosocomial infections and is a threat to healthcare settings. It has also developed multidrug resistance (MDR) capacity. The nosocomial bacteria and antibiotic resistance are primordial and a significant public health concern. These bacteria and their threat can be prevented by reducing infected food...